404-26-2

Usage

Chemical Properties

White Solid

Uses

Intermediate in the production of Folic Acid

InChI:InChI=1/C9H6F3NO3/c10-9(11,12)8(16)13-6-3-1-5(2-4-6)7(14)15/h1-4H,(H,13,16)(H,14,15)

Upstream product

• 383-64-2 S-ethyl trifluoroacetate 
• 150-13-0 4-amino-benzoic acid 
• 407-25-0 trifluoroacetic anhydride 
• 76-05-1 trifluoroacetic acid 
• 124-38-9 carbon dioxide 
• 126063-08-9 2,2,2-trifluoro-N-(4-iodophenyl)acetamide 
• 540-37-4 p-aminoiodobenzene 
• 56-91-7 p-aminomethylbenzoic acid 

Downstream Products

• 155112-15-5 3,5-Dinitro-4-(trifluoroacetamido)benzoic acid 
• 457-52-3 4-(2,2,2-trifluoro-acetylamino)-benzoyl chloride 
• 233600-78-7 dimethyl p-trifluoroacetamidobenzoyl-L-glutamate 
• 233600-89-0 <3',3',4',4'-(2)H4>-p-aminobenzoyl-L-glutamic acid 
• 233600-88-9 <3',3',4',4'-(2)H4>-dimethyl p-trifluoroacetamidobenzoyl-L-glutamate 
• 150-13-0 4-amino-benzoic acid 
• 197368-49-3 BDZ-2 
• 207238-95-7 {6-[4-(2,2,2-Trifluoro-acetylamino)-benzoyl]-benzo[1,3]dioxol-5-yl}-acetic acid methyl ester 
• 201678-01-5 4-Amino-benzoic acid 2-trimethylsilanyl-ethyl ester 
• 212118-12-2 4-(2,2,2-Trifluoro-acetylamino)-benzoic acid 2-trimethylsilanyl-ethyl ester 
• 212118-25-7 4-[(2E,4E)-3-Methyl-5-(2,6,6-trimethyl-cyclohex-1-enyl)-penta-2,4-dienoylamino]-benzoic acid 2-trimethylsilanyl-ethyl ester 
• 212118-18-8 4-[(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-quinoxaline-2-carbonyl)-amino]-benzoic acid 2-trimethylsilanyl-ethyl ester 
• 1207170-36-2 C₁₇H₂₂F₃N₅O₅ 
• 304646-56-8 methyl 4-(2,2,2-trifluoroacetamido)benzoate 

Relevant academic research and scientific papers

Selective HDAC inhibitors with potent oral activity against leukemia and colorectal cancer: Design, structure-activity relationship and anti-tumor activity study

Previously, we reported the discovery of a series of N-hydroxycinnamamide-based HDAC inhibitors, among which compound 11y exhibited high HDAC1/3 selectivity. In this current study, structural derivatization of 11y led to a new series of benzamide based HDAC inhibitors. Most of the compounds exhibited high HDACs inhibitory potency. Compound 11a (with 4-methoxybenzoyl as N-substituent in the cap and 4-(aminomethyl) benzoyl as the linker group) exhibited selectivity against HDAC1 to some extent, and showed potent antiproliferative activity against several tumor cell lines. In?vivo studies revealed that compound 11a displayed potent oral antitumor activity in both hematological tumor cell U937 xenograft model and solid tumor cell HCT116 xenograft model with no obvious toxicity. Further modification of benzamide 3, 11a and 19 afforded new thienyl and phenyl compounds (50a, 50b, 63a, 63b and 63c) with dramatic HDAC1 and HDAC2 dual selectivity, and the fluorine containing compound 56, with moderate HDAC3 selectivity.

PYRAZOLONE DERIVATIVE HAVING CYCLIC SIDE CHAIN

PROBLEM TO BE SOLVED: To provide a compound that has excellent inhibitory action on ATPase activity of TIP48/TIP49 complex and is therefore useful for the treatment of tumor, or a pharmacologically acceptable salt thereof. SOLUTION: The present invention provides a compound having a structure represented by general formula (I), its pharmacologically acceptable salt, or a pharmaceutical composition comprising the compound (where R1, R2, R3, R4, R5, R6, R7, W, and Z are as defined in the specifications). SELECTED DRAWING: None COPYRIGHT: (C)2016,JPOandINPIT

Discovery of multi-target anticancer agents based on HDAC inhibitor MS-275 and 5-FU

Histone deacetylases (HDACs) inhibitors have multiple effects targeting the cancer cells and have become one of the promising cancer therapeutics with possibly broad applicability. Combination of HDAC inhibitors with the cytotoxic fluorouracil (5-FU) show

THERAPEUTIC COMPOUNDS AND COMPOSITIONS

Compounds of general formula (I) and compositions comprising compounds of general formula I that modulate pyruvate kinase are described herein. Also described herein are methods of using the compounds that modulate pyruvate kinase in the treatment of diseases.

THERAPEUTIC COMPOUNDS AND COMPOSITIONS

Compounds of general formula I: and compositions comprising compounds of general formula I that modulate pyruvate kinase are described herein. Also described herein are methods of using the compounds that modulate pyruvate kinase in the treatment of diseases.

THERAPEUTIC COMPOUNDS AND COMPOSITIONS

Compounds of general formula (I) and compositions comprising compounds of general formula (I) that modulate pyruvate kinase are described herein. Also described herein are methods of using the compounds that modulate pyruvate kinase in the treatment of diseases.

Tyrosine bioconjugation through aqueous ene-type reactions: A click-like reaction for tyrosine

(Figure Presented) A new and versatile class of cyclic diazodicarboxamides that reacts efficiently and selectively with phenols and the phenolic side chain of tyrosine through an ene-like reaction is reported. This mild aqueous tyrosine ligation reaction works over a broad pH range and expands the repertoire of aqueous chemistries available for small molecule, peptide, and protein modification. The tyrosine ligation reactions are shown to be compatible with the labeling of native enzymes and antibodies in a buffered aqueous solution. This reaction provides a novel synthetic approach to bispecific antibodies. We believe this reaction will find broad utility in peptide and protein chemistry and in the chemistry of phenol-containing compounds.

Quantitation of folates and their catabolites in blood plasma, erythrocytes, and urine by stable isotope dilution assays

New stable isotope dilution assays were developed for the simultaneous quantitation of the folates 5-methyltetrahydrofolic acid, 5-formyltetrahydrofolic acid, tetrahydrofolic acid, 10-formylfolic acid, and folic acid as well as for their catabolites para-aminobenzoylglutamate (pABG) and acetyl-para-aminobenzoylglutamate (ApABG) in clinical samples. The methods were based on cleanup by strong anion exchange followed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) detection. Deuterated analogues of the folates and [13C5]-labeled isotopologues of the catabolites were applied as the internal standards in stable isotope dilution assays. Extraction in 4-morpholineethanesulfonic acid (MES) buffer at pH 5.0 ensured the optimum stability of folates and, in combination with solid-phase extraction (SPE) based on strong anion exchange, resulted in higher recoveries compared with other combinations of extraction buffers and SPE. The method was sensitive enough to detect pABG in plasma generally and unmetabolized folic acid in the plasma of a volunteer after oral dosage of an aqueous folic acid solution. The sum of folate catabolites increased by a factor of 2 in the urine of the latter volunteer, compared with that resulting when only water was dosed.

HETEROCYCLIC ANTIVIRAL COMPOUNDS

Compounds having the formula I wherein A, R1, R2, R3, R4a, R4b, R4c, R5, R6, R7a, R7b, Ar1, Rc, Rd, Re/sup

Design of antiangiogenic hypoxic cell radiosensitizers: 2-Nitroimidazoles containing a 2-aminomethylene-4-cyclopentene-1,3-dione moiety

We designed chiral 2-nitroimidazole derivatives containing a 2-aminomethylene-4-cyclopentene-1,3-dione moiety as antiangiogenic hypoxic cell radiosensitizers. Based on results of molecular orbital calculations, the 2-aminomethylene-4-cyclopentene-1,3-dion